151 related articles for article (PubMed ID: 37505107)
1. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
Onishi N; Bareng TJ; Gibbs J; Li W; Price ER; Joe BN; Kornak J; Esserman LJ; Newitt DC; Hylton NM; ;
Radiol Imaging Cancer; 2023 Jul; 5(4):e220126. PubMed ID: 37505107
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
[TBL] [Abstract][Full Text] [Related]
3. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
4. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
Musall BC; Abdelhafez AH; Adrada BE; Candelaria RP; Mohamed RMM; Boge M; Le-Petross H; Arribas E; Lane DL; Spak DA; Leung JWT; Hwang KP; Son JB; Elshafeey NA; Mahmoud HS; Wei P; Sun J; Zhang S; White JB; Ravenberg EE; Litton JK; Damodaran S; Thompson AM; Moulder SL; Yang WT; Pagel MD; Rauch GM; Ma J
J Magn Reson Imaging; 2021 Jul; 54(1):251-260. PubMed ID: 33586845
[TBL] [Abstract][Full Text] [Related]
5. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
Onishi N; Li W; Gibbs J; Wilmes LJ; Nguyen A; Jones EF; Arasu V; Kornak J; Joe BN; Esserman LJ; Newitt DC; Hylton NM
Tomography; 2020 Jun; 6(2):77-85. PubMed ID: 32548283
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
[TBL] [Abstract][Full Text] [Related]
7. Deep Learning-Based Segmentation of Locally Advanced Breast Cancer on MRI in Relation to Residual Cancer Burden: A Multi-Institutional Cohort Study.
Janse MHA; Janssen LM; van der Velden BHM; Moman MR; Wolters-van der Ben EJM; Kock MCJM; Viergever MA; van Diest PJ; Gilhuijs KGA
J Magn Reson Imaging; 2023 Dec; 58(6):1739-1749. PubMed ID: 36928988
[TBL] [Abstract][Full Text] [Related]
8. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
Arasu VA; Kim P; Li W; Strand F; McHargue C; Harnish R; Newitt DC; Jones EF; Glymour MM; Kornak J; Esserman LJ; Hylton NM;
J Breast Imaging; 2020 Aug; 2(4):352-360. PubMed ID: 32803155
[TBL] [Abstract][Full Text] [Related]
10. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
Li W; Partridge SC; Newitt DC; Steingrimsson J; Marques HS; Bolan PJ; Hirano M; Bearce BA; Kalpathy-Cramer J; Boss MA; Teng X; Zhang J; Cai J; Kontos D; Cohen EA; Mankowski WC; Liu M; Ha R; Pellicer-Valero OJ; Maier-Hein K; Rabinovici-Cohen S; Tlusty T; Ozery-Flato M; Parekh VS; Jacobs MA; Yan R; Sung K; Kazerouni AS; DiCarlo JC; Yankeelov TE; Chenevert TL; Hylton NM
Radiol Imaging Cancer; 2024 Jan; 6(1):e230033. PubMed ID: 38180338
[TBL] [Abstract][Full Text] [Related]
11. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI.
Cao Y; Wang X; Li L; Shi J; Zeng X; Huang Y; Chen H; Jiang F; Yin T; Nickel D; Zhang J
Diagn Interv Imaging; 2023 Dec; 104(12):605-614. PubMed ID: 37543490
[TBL] [Abstract][Full Text] [Related]
13.
Diwanji D; Onishi N; Hathi DK; Lawhn-Heath C; Kornak J; Li W; Guo R; Molina-Vega J; Seo Y; Flavell RR; Heditsian D; Brain S; Esserman LJ; Joe BN; Hylton NM; Jones EF; Ray KM
Radiol Imaging Cancer; 2024 Mar; 6(2):e230082. PubMed ID: 38551406
[TBL] [Abstract][Full Text] [Related]
14. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
[TBL] [Abstract][Full Text] [Related]
15. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
[TBL] [Abstract][Full Text] [Related]
16. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
Wu J; Gong G; Cui Y; Li R
J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
[TBL] [Abstract][Full Text] [Related]
17. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
[TBL] [Abstract][Full Text] [Related]
18. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Magbanua MJM; Li W; Wolf DM; Yau C; Hirst GL; Swigart LB; Newitt DC; Gibbs J; Delson AL; Kalashnikova E; Aleshin A; Zimmermann B; Chien AJ; Tripathy D; Esserman L; Hylton N; van 't Veer L
NPJ Breast Cancer; 2021 Mar; 7(1):32. PubMed ID: 33767190
[TBL] [Abstract][Full Text] [Related]
20. Time Course Changes of Synthetic Relaxation Time During Neoadjuvant Chemotherapy in Breast Cancer: The Optimal Parameter for Treatment Response Evaluation.
Zhao R; Du S; Gao S; Shi J; Zhang L
J Magn Reson Imaging; 2023 Oct; 58(4):1290-1302. PubMed ID: 36621982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
